WHI-P154
CAS No. 211555-04-3
WHI-P154 ( JAK3 Inhibitor II; Janus-Associated Kinase 3 Inhibitor II )
Catalog No. M13364 CAS No. 211555-04-3
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 32 | In Stock |
|
5MG | 50 | In Stock |
|
10MG | 79 | In Stock |
|
25MG | 167 | In Stock |
|
50MG | 314 | In Stock |
|
100MG | 510 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWHI-P154
-
NoteResearch use only, not for human use.
-
Brief DescriptionWHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
-
DescriptionWHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
-
SynonymsJAK3 Inhibitor II; Janus-Associated Kinase 3 Inhibitor II
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR; JAK3; Src; VEGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number211555-04-3
-
Formula Weight376.20
-
Molecular FormulaC16H14BrN3O3
-
Purity>98%(HPLC)
-
SolubilityDMSO: 75 mg/mL (199.36 mM)
-
SMILESOC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1Br
-
Chemical Name2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.O'Donoghue ML, et al. J Thromb Thrombolysis. 2012 Jul;34(1):36-43.
molnova catalog
related products
-
Naquotinib
Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR.
-
Mobocertinib
Mobocertinib is a potent ?inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent.
-
Oritinib
Oritinib is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d746-750), EGFR (d746-750/T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.